Understanding how certain cancers respond to Notch inhibitors
Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11082432
This study is looking into why some people with mantle cell lymphoma and chronic lymphocytic leukemia benefit from Notch inhibitors while others don’t, hoping to find clues in their genes that could help create better treatments for everyone.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11082432 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms that determine why some patients with mantle cell lymphoma and chronic lymphocytic leukemia respond to Notch inhibitors while others do not. By examining the genetic and epigenetic factors involved, the study aims to identify how Notch mutations influence treatment outcomes. The researchers will utilize advanced techniques such as functional genomics and genome engineering to analyze cancer cells at a detailed level. This approach seeks to uncover the underlying biology that could lead to more effective therapies for patients with these types of blood cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mantle cell lymphoma or chronic lymphocytic leukemia, particularly those with Notch mutations.
Not a fit: Patients without mantle cell lymphoma or chronic lymphocytic leukemia, or those who do not have Notch mutations, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with mantle cell lymphoma and chronic lymphocytic leukemia.
How similar studies have performed: Previous research has shown promise in targeting Notch pathways in other cancers, suggesting potential for success in this area as well.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FARYABI, ROBERT BABAK — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: FARYABI, ROBERT BABAK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: addictive disorder